20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
The European Commission has approved Deciphera Pharmaceuticals Inc's (NASDAQ:DCPH) Qinlock (ripretinib)for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
- In September 2021, Qinlock was added as a fourth-line treatment for GIST patients progressing or intolerant to imatinib, sunitinib, and regorafenib, to the ESMO-EURACAN-GENTURIS clinical practice guidelines for GIST2.
- Related Link: Why Did Deciphera Stock Plunge 70% Today?
- The approval was supported by efficacy results from the primary analysis of the pivotal Phase 3 INVICTUS study.
- The trial demonstrated a median progression-free survival of 6.3 months compared to 1.0 month in the placebo arm.
- It reduced the risk of disease progression or death by 85%
- Price Action: DCPH shares are up 1.64% at $8.64 during the market session on Monday's last check.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!